3-(1-t-butyloxycarbonyl-(2S)-azetidinylmethoxy)-6-chloropyridine | 203564-52-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 3-(1-t-butyloxycarbonyl-(2S)-azetidinylmethoxy)-6-chloropyridine
• 英文别名: tert-butyl (2S)-2-[(6-chloropyridin-3-yl)oxymethyl]azetidine-1-carboxylate
• CAS: 203564-52-7
• 化学式: C₁₄H₁₉ClN₂O₃
• 分子量: 298.769
• InChiKey: UCVBLDPGVWBCKG-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(1-t-butyloxycarbonyl-(2S)-azetidinylmethoxy)-6-chloropyridine 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 生成 (S)-5-(2-azetidinyl-methoxy)-2-chloropyridine
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine Receptors

  摘要：

  New members of a previously reported series of 3-pyridyl ether compounds are disclosed as novel, potent analgesic agents acting through neuronal nicotinic acetylcholine receptors. Both (R)-2-chloro-5-(2-azetidinylmethoxy)pyridine (ABT-594, 5) and its S-enantiomer (4) show potent analgesic activity in the mouse hot-plate assay following either intraperitoneal (ip) or oral (po) administration, as well as activity in the mouse abdominal constriction (writhing) assay, a model of persistent pain. Compared to the S-enantiomer and to the prototypical potent nicotinic analgesic agent (+/-)-epibatidine, 5 shows diminished activity in models of peripheral side effects. Structure-activity studies of analogues related to 4 and 5 suggest that the N-unsubstituted azetidine moiety and the 2-chloro substituent on the pyridine ring are important contributors to potent analgesic activity.

  DOI：

  10.1021/jm9706224
• 作为产物：
  描述：

  ((S)-1-(tert-butoxycarbonyl)azetidin-2-yl)methyl 4-methylbenzenesulfonate 在 氢氧化钾 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-(1-t-butyloxycarbonyl-(2S)-azetidinylmethoxy)-6-chloropyridine
  参考文献：
  名称：

  3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission

  摘要：

  新型3-吡啶氧甲基杂环醚化合物的化学式为： 或其药学上可接受的盐或前药是神经元胆碱能受体选择性和有效的配体，并且在控制突触传递方面具有良好效果。还描述了使用这些关键中间体的关键中间体和过程，以生产具有规范中定义的变量的化合物I的方法。

  公开号：

  US06437138B1

文献信息

• Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: Effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice
  作者：Mark W. Holladay、Hao Bai、Yihong Li、Nan-Horng Lin、Jerome F. Daanen、Keith B. Ryther、James T. Wasicak、John F. Kincaid、Yun He、Anne-Marie Hettinger、Peggy Huang、David J. Anderson、Anthony W. Bannon、Michael J. Buckley、Jeffrey E. Campbell、Diana L. Donnelly-Roberts、Karen L. Gunther、David J.B. Kim、Theresa A. Kuntzweiler、James P. Sullivan、Michael W. Decker、Stephen P. Arneric

  DOI：10.1016/s0960-894x(98)00504-6

  日期：1998.10

  tested for affinity to nicotinic acetylcholine receptor binding sites in rat brain and for analgesic activity in the mouse hot plate assay. Numerous types of modifications were consistent with high affinity for [3H]cytisine binding sites. By contrast, only selected modifications resulted in retention of analgesic potency in the same range as 1 and 2. Analogs of 2 with one or two methyl substituents at

  制备了类似物A-98593（1）及其对映体ABT-594（2），在吡啶环上具有多个取代基，并测试了与大鼠脑中烟碱乙酰胆碱受体结合位点的亲和力以及在小鼠热板测定中的镇痛活性。多种修饰类型与对[3H]胱氨酸结合位点的高亲和力相一致。相比之下，仅选择的修饰导致止痛效果保持在与1和2相同的范围内。还制备了在氮杂环丁烷环的3位带有一个或两个甲基取代基的2的类似物，发现它们的活性实质上较低。两种测定。
• [EN] HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION<br/>[FR] COMPOSES ETHER ET THIOETHER HETEROCYCLIQUES UTILISES DANS LA REGULATION DE LA TRANSMISSION SYNAPTIQUE CHIMIQUE
  申请人：ABBOTT LABORATORIES

  公开号：WO1999032480A1

  公开（公告）日：1999-07-01

  (EN) Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.(FR) L'invention porte sur de nouveaux composés ayant les formules (I), (II) ou (III), ou sur leurs sels pharmaceutiquement acceptables ou promédicaments, et qui sont utilisés dans la régulation de la transmission synaptique. L'invention porte également sur les compositions pharmaceutiques thérapeutiquement efficaces de ces composés, et sur l'utilisation de ces compositions pour réguler la transmission synaptique chez l'homme ou l'animal.

  （中文翻译）本发明涉及具有公式（I），（II）或（III）或其药学上可接受的盐或前药的新化合物，其用于控制突触传递；以及这些化合物的治疗有效的药物组合物，以及使用该组合物在人类或兽医患者中控制突触传递的用途。
• 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling
  申请人：Abbott Laboratories

  公开号：US05629325A1

  公开（公告）日：1997-05-13

  Novel 3-pyridyloxymethyl heterocyclic ether compounds of the formula: ##STR1## or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission.

  以下是翻译结果： 式子为：##STR1## 的新型3-吡啶氧甲基杂环醚化合物，或其药学上可接受的盐或前药，是神经元乙酰胆碱受体选择性和有效的配体，并且在控制突触传递方面具有良好的效果。
• Methods for identifying novel multimeric agents that modulate receptors
  申请人：——

  公开号：US20030087306A1

  公开（公告）日：2003-05-08

  Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same of different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

  本发明揭示了新型的多重结合化合物（试剂），其能够结合细胞受体。本发明的化合物包括多个配体，每个配体都能够结合到这些细胞受体上，从而调节其生物过程/功能。每个配体均与一个连接剂或连接剂共价结合，这些连接剂可以相同或不同，以提供多重结合化合物。所选择的连接剂使得所构建的多重结合化合物表现出对细胞生物过程/功能的增强调节或干扰。本发明还揭示了一种识别能够结合细胞受体的新型多重结合化合物的方法，以及一种生成这种新型多重结合化合物混合物的方法。
• 3-Pyridyl enantiomers and their use as analgesics
  申请人：Abbott Laboratories

  公开号：US06403575B1

  公开（公告）日：2002-06-11

  The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

  本发明涉及一种用于控制哺乳动物（包括人类）疼痛的方法，包括向需要治疗的哺乳动物或患者施用公式I的选定化合物或其药学上可接受的盐。本发明进一步涉及公式I中选定的(R)和(S)化合物，其可用作镇痛剂，同时还可以预防神经元细胞死亡和抗炎。